---
title: Improve arm dexterity with robotics
nct_id: NCT06906679
phase: NA
status: RECRUITING
sponsor: IRCCS San Raffaele Roma
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06906679"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06906679"
last_fetched: "2026-05-10T14:06:01.916Z"
source: "Parkinson's Pathways (curated)"
---
# Improve arm dexterity with robotics

**Goal (in five words):** Improve arm dexterity with robotics

**Official Title:** Effectiveness of a Robotic End-effector Device for Upper Limb Rehabilitation in People With Parkinson's Disease: a Multicenter Randomized Controlled Pilot Study

**Trial ID:** [NCT06906679](https://clinicaltrials.gov/study/NCT06906679)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** IRCCS San Raffaele Roma
- **Target Enrollment:** 40 participants
- **Start Date:** 2023-12-20
- **Completion Date:** 2025-12-20
- **Conditions:** Parkinson Disease
- **Interventions:** Experimental Group, control group
- **Intervention Types:** DEVICE, OTHER

## Summary For Families

The goal is to help people with moderate Parkinson's improve upper limb movement, strength, coordination and everyday arm use. A robotic end-effector device attaches at the hand or wrist and guides repetitive, assisted reaching, grasping and fine-motor exercises, giving consistent movement patterns and sensory feedback to promote motor relearning and reduce stiffness; the multicenter trial randomly compares robot-assisted sessions to standard care. They are enrolling about 40 people aged 30 to 80 with Parkinson's by UK Brain Bank criteria, Hoehn and Yahr stage 2 to 3 while ON, a MoCA score of at least 17.54, stable medications for 4 or more weeks, and the ability to follow and consent to the exercise program.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age between 30 and 80 years;
* Diagnosis of Parkinson's disease according to the UK Parkinson's Disease Society Brain Bank criteria;
* Hoehn \& Yahr scale score between 2 and 3 in the "ON" phase;
* Montreal Cognitive Assessment (MoCA) screening test with a score ≥ 17.54;
* Stable pharmacological therapy for at least 4 weeks and throughout the treatment;
* Ability to understand and sign the informed consent for the study;
* Signed informed consent for the study;
* Ability to comply with the study procedures.

Exclusion Criteria:

* Unable to adhere to the exercise program due to poor compliance;
* Neurological disorders overlapping with Parkinson's disease, psychiatric complications, or personality disorders;
* Presence of osteoarticular and neuromuscular diseases that may impair upper limb mobility;
* Participants who have not signed the informed consent for the study.
```

## Locations (2)

- San Raffaele Cassino, Cassino, FR, Italy _(41.4858, 13.8284)_
  - Prof. Maria Francesca Francesca De Pandis, MD, PhD — (CONTACT) — +39077639740 — maria.depandis@sanraffaele.it
  - Prof. Maria Francesca De Pandis, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- IRCCS San Raffaele Roma, Rome, Lazio, Italy _(41.8919, 12.5113)_
  - Dr. Sanaz Pournajaf, DPT — (CONTACT) — +39 0652252405 — sanaz.pournajfa@sanraffaele.it
  - Dr. Sanaz Pournajaf, DPT — (SUB_INVESTIGATOR)

## Central Contacts

- Dr. Sanaz Pournajaf, DPT — (CONTACT) — +39 0652252405 — sanaz.pournajfa@sanraffaele.it
- Dr. Carrie Louise Thouant, OT — (CONTACT) — carrielouise.thouant@sanraffaele.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06906679*  
*HTML version: https://parkinsonspathways.com/trial/NCT06906679*  
*Source data: https://clinicaltrials.gov/study/NCT06906679*